Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 6/2024

30-11-2023 | Hemolytic Uremic Syndrome | Research Letter

Eculizumab in STEC-HUS with severe neurological involvement: a New Zealand perspective

Authors: Nithiakishna Selvathesan, William Wong, Chanel Prestidge

Published in: Pediatric Nephrology | Issue 6/2024

Login to get access

Excerpt

There is an emerging paradigm shift to the use of C5-complement inhibitor eculizumab as a rescue therapy in patients with neurological involvement in Shiga toxin–producing Escherichia coli (STEC)-hemolytic uremic syndrome (HUS). With the paucity of data in this context, we offer our national experience from New Zealand. …
Literature
1.
Wong W (2021) Shiga toxin producing Escherichia coli infections and associated haemolytic uraemic syndrome in New Zealand children: twenty three years of epidemiology and clinical observations. Int J Pediatr Res 8:085
2.
3.
Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (20215) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94:e1000
4.
Giordano P, Netti GS, Santangelo L, Castellano G, Carbone V, Torres DD et al (2019) A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Pediatr Nephrol 34:517–527CrossRefPubMed
Metadata
Title
Eculizumab in STEC-HUS with severe neurological involvement: a New Zealand perspective
Authors
Nithiakishna Selvathesan
William Wong
Chanel Prestidge
Publication date
30-11-2023
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 6/2024
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-023-06226-z

Other articles of this Issue 6/2024

Pediatric Nephrology 6/2024 Go to the issue

Original Article

Pediatric urogenital schistosomiasis diagnosed in France

Original Article

Anti-factor B antibodies in atypical hemolytic uremic syndrome

Original Article

A 6-year review of acute post-streptococcal glomerulonephritis at a public children’s hospital in Cape Town, South Africa

Original Article

Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?

Original Article

Ongoing impacts of childhood-onset glomerular diseases during young adulthood

Original Article

Müllerian anomalies in girls with congenital solitary kidney